Investigation of Obstructive Sleep Apnea Using Portable Monitors and Health Check Data in Japanese Drivers

Masako Ueyama¹, Hiroyuki Kokuto², Hitoshi Sugihara³, Shinichi Oikawa⁴, Fumio Suzuki¹, Hajime Goto² and Shoji Kudoh⁵

¹ Department of Health Care, Fukuji Hospital, Japan Anti-Tuberculosis Association, Kiyose, Tokyo, Japan
² Department of Respiratory Medicine, Fukuji Hospital Japan Anti-Tuberculosis Association, Kiyose, Tokyo, Japan
³ Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Nippon Medical School, Bunkyo, Tokyo, Japan
⁴ Diabetes and Lifestyle-related Disease Center, Fukuji Hospital, Japan Anti-Tuberculosis Association, Kiyose, Tokyo, Japan
⁵ Japan Anti-Tuberculosis Association, Chiyoda, Tokyo, Japan

Aims: The identification and appropriate management of commercial motor vehicle (CMV) drivers with unrecognized obstructive sleep apnea (OSA) is a major public health concern and priority; OSA among drivers has not been fully investigated in Japan, and a better understanding of this undiagnosed disease is warranted. Therefore, we evaluated the prevalence of OSA and the factors related to apnea–hypopnea index (AHI) in Japanese CMV drivers.

Methods: This retrospective study included 1309 Japanese CMV drivers aged 40–69 years. All the subjects received type IV portable sleep monitors (PMs) with Epworth Sleepiness Scale (ESS) and a periodic health check including anthropometrical and laboratory measurements, and a questionnaire of medical history, smoking status, and life style, following which variables related to AHI were analyzed.

Results: Of all the subjects, 23.9% had moderate to severe OSA (AHI ≥15). Age, body mass index (BMI), LogeHbA1c and diastolic blood pressure (DBP) showed significance with AHI in 1309 subjects. The following factors were found to have significant odds ratio (OR) for AHI of ≥15 in 1309 subjects: age, ESS, DBP, and LogeHbA1c.

Conclusion: Notably, drivers with undiagnosed OSA exist. In these subjects, AHI was related to obesity, hypertension, and diabetes. For the early diagnosis and intervention of OSA, BMI, blood pressure, and HbA1c measurements may be helpful, particularly for drivers. Furthermore, when performing an objective assessment of the suspected OSA, evaluating these parameters during routine medical check-ups may be useful and feasible in the detection of drivers with latent OSA.

Key words: Obstructive Sleep Apnea Syndrome, Sleep-Disordered Breathing, Occupational Health, Commercial motor vehicle drivers

Introduction

Till date, there have been only a few investigations of the relationship between obstructive sleep apnea (OSA) and Japanese commercial motor vehicle (CMV) drivers¹, ², even though the identification, and appropriate management of CMV drivers with unrecognized OSA is a major public health concern and priority. Furthermore, it is well known that OSA leads to intermittent hypoxia, enhanced sympathetic activity, and increased oxidative stress³. Obesity is a major risk factor for snoring and sleep apnea, and most patients with OSA are overweight⁴. Previous reports have shown OSA to be associated with increased risk of hypertension⁵, ⁶, stroke⁷, ⁸, coronary artery disease⁹, ¹⁰, insulin resistance¹¹, ¹² and metabolic syndrome¹³, ¹⁴.
Concerning traffic accidents, unintentionally falling asleep, nodding off while driving and having difficulty performing daily tasks because of sleepiness may all contribute to hazardous outcomes\textsuperscript{15}. The National Department of Transportation estimates drowsy driving to be responsible for 1,550 fatalities and 40,000 nonfatal injuries annually in the United States\textsuperscript{16}. In Japan, fatal traffic accidents of commercial transportation vehicles numbered 5448 cases in 2013\textsuperscript{17}. Despite these accident reports documented by the government, epidemiological investigation on OSA in drivers has not yet been fully addressed in Japan. There may be many undiagnosed and untreated CMV drivers suffering from OSA and its related diseases, and these drivers may pose a risk to public safety. A better understanding of OSA in CMV drivers is therefore a major public health and trucking industry priority. As noted, it is essential that early diagnosis and intervention are required not only to reduce fatal traffic or industrial accidents but also for the drivers’ health. Therefore, the aim of this study is to evaluate the prevalence of OSA and the factors associated with high apnea–hypopnea index (AHI) among 1309 Japanese drivers using type IV portable sleep monitors (PMs) and data from health check-ups.

**Methods**

**Study Subjects**

This cross-sectional study included professional CMV drivers working for a transport company in Japan. Between January 2011 and December 2014, 1720 drivers working at the company randomly received type IV PMs between January 2011 and December 2014 with the Epworth Sleepiness Scale (ESS), as described below. We analyzed PMs’ data together with periodic health check data that included a specific questionnaire, anthropometrical measurements, and laboratory assessments. Because of health insurance association membership regulations in Japan, 1309 of the 1720 drivers were required to complete a specific questionnaire and those 1309 drivers were analyzed in this study (Fig. 1). Most study subjects were men and only 22 (1.68%) women were included. The age distribution was as follows: 47.7% were aged 40–49 years, 38.6% were aged 50–59 years and 13.7% were aged ≥60 years. No subject had been diagnosed with, or had received treatment for sleep apnea. Informed consent was obtained from all participants by comprehensive agreement. The institutional review board of our hospital approved this study (#17002), which was conducted in accordance with the principles of the Declaration of Helsinki.

**Measurements**

The principal objective of this study was to assess the relationship between OSA severity (measured categorically using the AHI) and anthropometric, clinical, and laboratory data obtained from nationwide specific health check-up data. The modified Japanese version of the ESS\textsuperscript{18} was used to assess subjective sleepiness. The subjects also completed specific questionnaire that covered their current and past medical history, their smoking status, and whether they had gained ≥10 kg in weight since the age of 20 years. A current smoker was defined as a subject who smokes ≥100 cigarettes or who has smoked for at least 6 months and in the last month. Trained nurse staff measured their height, weight, waist circumference at the level of the navel, and systolic
and diastolic blood pressure using an automated digital blood pressure monitor (BP-103i II; Omron Healthcare, Kyoto, Japan). Subjects were required to fast for 10 h or for as long as possible. Finally, fasting and non-fasting blood samples were obtained from 496 (37.9%) and 813 (62.1%) subjects, respectively. As part of the periodic mandatory workplace health check-up, venous blood was drawn at 15 branch offices of the company where the drivers work. Serum triglyceride level was measured using an enzymatic method (free glycerol-eliminated method). LDL- and HDL cholesterol were measured using a direct method with an automatic analyzer (TBA-c1600, Toshiba Medical Systems Corporation, Tochigi, Japan). HbA1c was measured using a HPLC method with an automatic analyzer (HLC-723®G8, Tosoh Corporation, Tokyo, Japan) at our hospital. Proteinuria was coded as (−), (±), (1+), (2+), and (3+), and positive proteinuria was defined as ≥ 1+. Other laboratory parameters were measured using specific health check-up data, and we investigated the relationship between AHI and these measurements.

Sleep Study

All subjects underwent a nocturnal, unattended sleep study at home using a type IV, 4-channel PM (SAS-2100; Nihon Kohden Co. Ltd., Tokyo, Japan) for one night. This recorded four physiological parameters: snoring, oxygen saturation (SpO2), heart rate (via a probe taped to a finger) and airflow (via a nasal pressure transducer). The device did not monitor body posture. The instructions for use illustrated the correct placement of the monitor. No specific limitations on daily life were imposed on the monitoring day; alcohol consumption was allowed in moderation. The subjects were asked to indicate the time they went to bed and the time they awoke the following morning. Our subsequent analysis was based on the automatic report from the accompanying software (QP-021W; Nihon Kohden), which analyzed the recording and presented the data. The expenses of PMs were borne by the transport company.

Respiratory events were scored according to the American Academy of Sleep Medicine criteria19. The oxygen desaturation index (ODI) was defined by the number of arterial oxygen saturation dips (≥ 3%) per hour of examination. Apnea events were defined as cessation of airflow for ≥ 10 s and hypopnea as a decrease of ≥ 50% from baseline in the amplitude of the nasal cannula airflow for ≥ 10 s during sleep associated with oxygen desaturation ≥ 3%. The AHI score was calculated from the number of apnea and hypopnea events per hour, using the total recording time as the denominator, and categorized as no sleep apnea (< 5), or mild (5–14.9), moderate (15–29.9) or severe (≥ 30) sleep apnea. Several studies have demonstrated a high sensitivity and specificity of the laboratory type IV portable monitor AHI compared with the AHI from the simultaneous PSG study at all AHI levels, at an AHI of ≥ 15 events per h (sensitivity, 91% and specificity, 95%; sensitivity, 100% and specificity, 92%, respectively)20, 21. The AHI comparison from the home IV portable monitor and laboratory PSG studies has also demonstrated good sensitivity and specificity at AHI levels of ≥ 5 (sensitivity, 81% and specificity, 77%; sensitivity, 92% and specificity, 77%, respectively) and at ≥ 15 events per h (sensitivity, 67% and specificity, 91%; sensitivity, 73% and specificity, 85%, respectively)21, 22.

Statistical Analysis

Data are expressed as mean ± SD, median (interquartile range) or percentage for the parametric, non-parametric, and categorical data, respectively. Because of skewed distribution, GOT, GPT, γ-GTP, TG, and HbA1c values were logarithmically transformed before the analysis. Baseline characteristics were compared between the four AHI categories using ANOVA with post hoc Tukey analysis, Kruskal–Wallis, and chi-squared tests for parametric, nonparametric, and categorical variables, respectively. Correlations between AHI and demographic, anthropometric, and laboratory variables were assessed by Pearson’s correlation coefficients. We included age, BMI, ESS, DBP, LogeGPT, Loge-HbA1c, and HDL-C in the multiple linear regression analysis using stepwise selection to evaluate AHI with each parameter. Multivariate logistic regression analysis was applied by adjusting for important AHI factors in univariate analyses, which were age, ESS, BMI, DBP, smoking history, body weight change, HDL-C, LogeGPT, and Loge-HbA1c using forced entry. Adjusted odds ratios (ORs) were estimated with 95% confidence interval (CI), referencing to that for participants with AHI of < 15. All statistical tests were two-tailed and a p-value of < 0.05 was considered statistically significant. SPSS version 22 software (IBM Corp., Armonk, NY, USA) was used for the analyses.

Results

Descriptive characteristics of the subjects and the distributions of the covariates, stratified by the four AHI categories, are presented in Table 1. The mean age of the 1309 drivers was 49.73 ± 6.77 years, 98.3% were men, and the median body mass index (BMI) was 23.9 kg/m². According to the AHI scores, 40.4% of the subjects did not have OSA (AHI < 5), whereas 23.9% had moderate to severe OSA (AHI ≥ 15). Those with more severe AHI were more obese and had a greater burden of cardiometabolic medication intake.
### Table 1. Demographic, clinical, and sleep monitor data categorized by the severity of apnea–hypopnea index*

|                                | Total population | 0–5 | 5 ≤ 15 | ≤ 15 | ≤ 30 | p-value |
|--------------------------------|------------------|-----|--------|------|------|---------|
| Number (%)                     | 1309 (100)       | 529 (40.4) | 467 (35.7) | 227 (17.3) | 86 (6.6) | <0.001  |
| Age (years)                    | 49.73 ± 6.77     | 48.96 ± 6.82 | 49.83 ± 6.71 | 50.55 ± 6.62 | 51.85 ± 6.57 | <0.001  |
| AHI (6.7)                      | (2.8–14.3)       | (1.1–3.4) | 8.3 (6.6–11.2) | 20.4 (17.4–24.7) | 38.7 (33.0–49.0) | <0.001  |
| ODI (3%)                       | 6.9 (3.2–13.4)   | 2.7 (1.5–4.0) | 8.4 (6.6–10.9) | 19.4 (16.1–22.9) | 36.3 (30.5–47.1) | <0.001  |
| ESS (5)                        | (3–8)            | (3–8) | (3–7) | (3–8) | (3–8) | 0.094   |
| BMI (kg/m²)                    | 23.9 (22–26.1)   | 22.6 (20.95–24.4) | 24 (22.5–26.2) | 25.8 (23.5–28.3) | 26.6 (24.6–30.4) | <0.001  |
| WC (cm)                        | 86 (80–92)       | 82 (77–87) | 87 (82–92) | 90 (85–96) | 93 (87–102) | <0.001  |
| SBP (mmHg)                     | 128.47 ± 14.93   | 125.45 ± 14.83 | 128.6 ± 14.04 | 132.98 ± 14.74 | 134.45 ± 16.06 | <0.001  |
| DBP (mmHg)                     | 79.82 ± 10.55    | 77.52 ± 10.65 | 80.07 ± 9.74 | 83.37 ± 10.01 | 83.23 ± 11.90 | <0.001  |
| WBC (/µL)                      | 6710 (5670–8085) | 6610 (5570–7990) | 6770 (5620–8040) | 6810 (5860–8360) | 6910 (6005–8497) | 0.056   |
| HbA1c (%)                      | 5.6 (5.4–5.9)    | 5.5 (5.4–5.8) | 5.6 (5.4–5.9) | 5.8 (5.5–6.2) | 5.8 (5.5–6.3) | <0.001  |
| Weight gain (>10 kg) (%)       | 632 (48.3)       | 175 (33.1) | 250 (53.5) | 143 (63.0) | 64 (74.4) | <0.001  |
| Current smoking (+) (%)        | 525 (40.1)       | 219 (41.4) | 184 (39.4) | 87 (38.3) | 35 (40.7) | 0.855   |
| Everyday drinking (+) (%)      | 343 (26.2)       | 125 (23.6) | 129 (27.6) | 63 (27.8) | 26 (30.2) | 0.347   |
| Proteinuria (1+, 2+) (%)       | 42 (3.2)         | 10 (1.9) | 12 (2.6) | 12 (5.3) | 8 (9.3) | 0.001   |
| Antihypertensive medicine intake (%) | 255 (19.5) | 64 (12.1) | 95 (20.3) | 61 (26.9) | 35 (40.7) | <0.001  |

*P-values denote the level of significance. Values in parentheses indicate the range of the data.
Discussion

The interesting point of this study is a large sample to examine OSA and health check data among professional drivers, which provides a more real situation of OSA severity and related status.

A major finding in our study was the 23.9% prevalence of moderate and severe OSA (AHI ≥ 15) among drivers aged 40–69 years. The prevalence of OSA in the general population varies across the world. These differences could be due to different monitoring methods and definitions for the apnea hypopnea scoring, as well as differences in study design and populations23-27. In a previous study on 1313 Japanese drivers aged 40–69 years, the prevalence of 3% ODI ≥ 15, as assessed by pulse oximetry, was 8.5%28. Compared with that, our study subjects showed higher AHI scores and were older, although the mean BMI was similar. Furthermore, 35% of our subjects had BMI > 25 compared with 31.6% of the Japanese population aged 20–69 years29. Therefore, considering the prevalence of obesity, our results showed that there may also be a much greater prevalence of undiagnosed (latent) OSA in the general Japanese population, than what we assumed.

Another important finding was that HbA1c also had a significant association with AHI scores (OR 6.512, 95% CI 2.219–19.115, p < 0.001) as shown in the previous studies29,30. However, the strength of this study is that we found these correlations particularly in drivers. In previous reports, OSA has been linked to the progression of diabetes independent of obesity, via activation of the sympathetic nervous system31. In other reports, cross-sectional estimates from clinical populations and population studies have suggested that

\[(\text{Cont Table 1})\]

| Total population | 0–15 | 5 ≤ 15 | ≤ 15 | ≤ 30 | p-value |
|------------------|------|-------|-----|------|--------|
| Antidiabetic medicine intake (%) | 75 (5.7) | 16 (3.0) | 25 (5.4) | 23 (10.1) | 11 (12.8) | < 0.001 |
| Antihyperlipidemic medicine intake (%) | 114 (8.7) | 30 (5.7) | 40 (8.6) | 32 (14.1) | 12 (14.0) | 0.001 |
| Brain stroke past history (+) (%) | 8 (0.6) | 2 (0.4) | 3 (0.6) | 2 (0.9) | 1 (1.2) | 0.757 |
| History of angina or MI (+) (%) | 19 (1.5) | 6 (1.1) | 6 (1.3) | 4 (1.8) | 3 (3.5) | 0.375 |
| History of CRF or dialysis (+) (%) | 1 (0.1) | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) | 0.189 |
| Cancer history (+) (%) | 9 (0.7) | 5 (0.9) | 1 (0.2) | 2 (0.9) | 1 (1.2) | 0.483 |

*Unless otherwise stated, data are presented as mean ± SD, median (interquartile range) or n (%).

AHI = apnea–hypopnea index; ODI = oxyhemoglobin desaturation index; ESS = Epworth sleepiness scale; BMI = body mass index; WC = waist circumference; SBP = systolic blood pressure; DBP = diastolic blood pressure; WBC = white blood cell; Hb = hemoglobin; Ht = hematocrit; GOT = glutamic oxalacetic transaminase; GPT = glutamic pyruvic transaminase; Cre = creatinine; γGTP = gamma-glutamyl transpeptidase; TG = triglycerides; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; UA = uric acid; HbA1c = glycosylated hemoglobin; MI = myocardial infarction; CRF = chronic renal failure.
Table 2. Pearson correlation coefficients of AHI with demographic, clinical, and anthropometric factors

| Variable          | Total C.C (r) | p-value | Model 1 C.C (r) | p-value |
|-------------------|---------------|---------|----------------|---------|
| ODI (3%)          | 0.98          | <0.001  | ODI (3%)       | 0.977   | <0.001  |
| BMI (kg/m²)       | 0.409         | <0.001  | BMI (kg/m²)    | 0.382   | <0.001  |
| WC (cm)           | 0.388         | <0.001  | WC (cm)        | 0.356   | <0.001  |
| DBP (mmHg)        | 0.209         | <0.001  | Log.GPT (IU/L) | 0.208   | <0.001  |
| Log.GPT (IU/L)    | 0.208         | <0.001  | DBP (mmHg)     | 0.208   | <0.001  |
| SBP (mmHg)        | 0.207         | <0.001  | Log.HbA1c (%)  | 0.207   | <0.001  |
| Log.HbA1c (%)     | 0.193         | <0.001  | SBP (mmHg)     | 0.206   | <0.001  |
| Log.TG (mg/dL)    | 0.146         | <0.001  | HDL-C (mg/dL)  | −0.154  | <0.001  |
| HDL-C (mg/dL)     | −0.141        | <0.001  | Log.TG (mg/dL) | 0.151   | <0.001  |
| Age               | 0.116         | <0.001  | UA (mg/dL)     | 0.122   | <0.001  |
| Log.γ-GTP (IU/L)  | 0.113         | <0.001  | Age            | 0.116   | <0.001  |
| Log.GOT (IU/L)    | 0.111         | <0.001  | Log.γ-GTP (IU/L)| 0.112  | <0.001  |
| Hb (g/dL)         | 0.094         | 0.001   | Hb (g/dL)      | 0.105   | 0.001   |
| UA (mg/dL)        | 0.093         | 0.001   | Log.GOT (IU/L) | 0.102   | 0.001   |
| Ht (%)            | 0.091         | 0.001   | Ht (%)         | 0.099   | 0.001   |
| WBC (µL)          | 0.087         | 0.002   | WBC (µL)       | 0.088   | 0.004   |
| LDL-C (mg/dL)     | 0.067         | 0.015   | LDL-C mg/dL    | 0.073   | 0.018   |
| ESS               | 0.038         | 0.17    | ESS            | 0.045   | 0.144   |
| Cre (mg/dL)       | 0.029         | 0.301   | Cre (mg/dL)    | 0.031   | 0.314   |

| Variable          | Model 2 C.C (r) | p-value | Model 3 C.C (r) | p-value |
|-------------------|-----------------|---------|-----------------|---------|
| ODI (3%)          | 0.979           | <0.001  | ODI (3%)        | 0.979   | <0.001  |
| BMI (kg/m²)       | 0.397           | <0.001  | BMI (kg/m²)     | 0.4     | <0.001  |
| WC (cm)           | 0.371           | <0.001  | WC (cm)         | 0.378   | <0.001  |
| Log.GPT (IU/L)    | 0.213           | <0.001  | SBP (mmHg)      | 0.206   | <0.001  |
| DBP (mmHg)        | 0.207           | <0.001  | Log.GPT (IU/L)  | 0.199   | <0.001  |
| SBP (mmHg)        | 0.19            | <0.001  | DBP (mmHg)      | 0.198   | <0.001  |
| Log.HbA1c (%)     | 0.185           | <0.001  | Log.HbA1c (%)   | 0.191   | <0.001  |
| HDL-C (mg/dL)     | −0.147          | <0.001  | Log.TG (mg/dL)  | 0.148   | <0.001  |
| Log.TG (mg/dL)    | 0.14            | <0.001  | HDL-C (mg/dL)   | −0.13   | <0.001  |
| Log.γ-GTP(IU/L)   | 0.122           | <0.001  | Age             | 0.128   | <0.001  |
| UA (mg/dL)        | 0.113           | <0.001  | Log.γ-GTP (IU/L)| 0.119   | <0.001  |
| Age               | 0.111           | <0.001  | Log.GOT (IU/L)  | 0.092   | 0.001   |
| Log.GOT (IU/L)    | 0.11            | <0.001  | LDL-C (mg/dL)   | 0.085   | 0.003   |
| Hb (g/dL)         | 0.089           | 0.002   | WBC (µL)        | 0.085   | 0.003   |
| WBC (µL)          | 0.085           | 0.003   | UA (mg/dL)      | 0.083   | 0.004   |
| Ht (%)            | 0.085           | 0.003   | Hb (g/dL)       | 0.077   | 0.008   |
| Cre mg/dL         | 0.067           | 0.019   | Ht (%)          | 0.076   | 0.008   |
| LDL-C (mg/dL)     | 0.058           | 0.041   | ESS             | 0.04    | 0.166   |
| ESS               | 0.046           | 0.109   | Cre (mg/dL)     | 0.002   | 0.954   |

In Model 1, 1054 subjects who do not take antihypertensive medicine were included. In Model 2, 1234 subjects who do not take antidiabetic medicine were included. In Model 3, 1195 subjects who do not take hyperlipidemic medicine were included.

C.C = correlation coefficient, AHI = apnea–hypopnea index; ODI = oxyhemoglobin desaturation index; BMI = body mass index; WC = waist circumference; HbA1c = glycosylated hemoglobin; GPT = glutamic pyruvic transaminase; SBP = systolic blood pressure; DBP = diastolic blood pressure; TG = triglyceride; γ-GTP = gamma-glutamyl transpeptidase; HDL-C = high-density lipoprotein cholesterol; WBC = white blood cell; GOT = glutamic oxalacetic transaminase; Hb = hemoglobin; UA = uric acid; Ht = hematocrit; LDL-C = low-density lipoprotein cholesterol; Cre = creatinine; ESS = Epworth sleepiness scale.
up to 40% of people with OSA have diabetes\textsuperscript{32, 33}. Likewise, in people who are known to have diabetes, the prevalence of OSA may be as much as 23%\textsuperscript{34}. HbA1c measurement has recently been approved of as a standalone test for type 2 diabetes by the American Diabetes Association\textsuperscript{35}, an accurate predictor of future type 2 diabetes and a better predictor of future cardiovascular illness and death than fasting plasma glucose\textsuperscript{36}. Of note, we would suggest that our data support the use of HbA1c as an effective, convenient, and inexpensive tool in drivers to identify diabetes earlier. Moreover, HbA1c is not affected by the dietary intake state and is feasible; therefore, we consider HbA1c to be a good comorbidity marker of diabetes in OSA drivers. Altogether, patients with moderate to severe OSA should always be warned with regard to the complications of diabetes in day-to-day medical examinations by health professionals.

Another remarkable finding was that only 120 subjects (9.17%) had ESS scores $\geq$ 11. Most of the subjects did not recognize subjective sleepiness and we presume that subjective self-reports require close attention in their interpretation. In previous studies in general settings, various types of questionnaires lacked sufficient sensitivity and specificity to replace a sleep study in diagnosing OSA\textsuperscript{37}. In particular, self-reporting appeared to be less reliable in an occupational setting\textsuperscript{38}. Every driver should therefore be required to undergo an objective physical examination such as BMI or blood pressure measurement as included in the Federal Motor Carrier Safety Administration standards\textsuperscript{39} and should be subjected to an accessible and feasible sleep study with PMs, even if there remain many unresolved issues with regard to PMs.

There are some important limitations in this study. First, almost all subjects were Japanese men and there were only a few women among drivers at a single company; therefore, the present findings may not be applicable to the general population, especially women. There are reports that the risk of OSA is less in women than in men before menopause, but women still experience more sleep problems than men\textsuperscript{40}; therefore, for validation in the general population, further research using PMs and health check data would be required to evaluate the heterogeneous group. Second, type IV PMs provide nasal airflow, oxygen saturation, and pulse information, but do not provide data related to sleep stages and body positioning unlike the standard PSG. Considering that PMs generally use recording time rather than total actual sleep time, the AHI obtained

---

**Table 3. Multivariate regression analysis of relationship of anthropometric, clinical and laboratory factors with AHI*\textsuperscript{*}**

|                      | Total, 1309 | Model 1 |
|----------------------|-------------|---------|
|                      | Adjusted $R^2$= 0.197 | Adjusted $R^2$= 0.181 |
|                      | standard $\beta$ | 95% CI | $p$-value | standard $\beta$ | 95% CI | $p$-value |
| Age                  | 0.13         | 0.132–0.301 | $<0.001$ | 0.121 | 0.1–0.275 | $< 0.001$ |
| BMI (kg/m$^2$)       | 0.38         | 1.018–1.350 | $<0.001$ | 0.343 | 0.827–1.177 | $< 0.001$ |
| Log HbA1c (%)        | 0.072        | 1.952–11.564 | 0.006  | 0.103 | 3.92–13.948 | $<0.001$ |
| DBP (mmHg)           | 0.073        | 0.023–0.134  | 0.006  | 0.082 | 0.023–0.134 | 0.006  |
| Log GPT              | N.A          | N.A       | N.A     | N.A   | N.A        | N.A     |

|                      | Model 2 | Model 3 |
|----------------------|---------|---------|
|                      | Adjusted $R^2$= 0.187 | Adjusted $R^2$= 0.190 |
|                      | standard $\beta$ | 95% CI | $p$-value | standard $\beta$ | 95% CI | $p$-value |
| Age                  | 0.135    | 0.133–0.304 | $<0.001$ | 0.151 | 0.162–0.332 | $<0.001$ |
| BMI (kg/m$^2$)       | 0.347    | 0.889–0.255  | $<0.001$ | 0.394 | 1.048–1.374 | $<0.001$ |
| Log HbA1c (%)        | 0.066    | 1.715–14.838 | 0.013  | 0.077 | 2.355–12.717 | 0.004  |
| DBP (mmHg)           | 0.061    | 0.007–0.119  | 0.028  | N.A   | N.A         | N.A     |
| Log GPT              | 0.063    | 0.118–2.431  | 0.031  | N.A   | N.A         | N.A     |

* We included age, BMI, ESS, DBP, HDL-C, Log HbA1c and Log GPT into the multiple linear regression analysis by stepwise selection.

AHI = apnea–hypopnea index; BMI = body mass index; ESS = Epworth sleepiness scale; HbA1c = glycosylated hemoglobin; DBP = diastolic blood pressure; GPT = glutamic pyruvic transaminase; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; N.A. = not applicable.

In Model 1, 1054 subjects who do not take antihypertensive medicine were included. In Model 2, 1234 subjects who do not take antidiabetic medicine were included. In Model 3, 1195 subjects who do not take hyperlipidemic medicine were included.

---

\textsuperscript{32} We included age, BMI, ESS, DBP, HDL-C, Log HbA1c and Log GPT into the multiple linear regression analysis by stepwise selection.

\textsuperscript{33} AHI = apnea–hypopnea index; BMI = body mass index; ESS = Epworth sleepiness scale; HbA1c = glycosylated hemoglobin; DBP = diastolic blood pressure; GPT = glutamic pyruvic transaminase; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; N.A. = not applicable.
OSA patients using objective measures such as PMs, although there are many difficulties in clarifying the optimal algorithm and results interpretation in testing OSA using PMs among drivers.

**Conclusion**

Our findings suggest that there exists a certain proportion of undiagnosed, mild to severe OSA in CMV drivers in Japan. Moreover, HbA1c was strongly associated with AHI, independent of age and obesity. From a practical standpoint, OSA drivers are always to be warned about the complication of hypertension or diabetes by the industrial or attending physician. Conversely, using periodic health check data, our study proposes that obesity, hypertension, and HbA1c eleva-
tion may indicate latent OSA in CMV drivers. Further prospective studies to examine the long-term causal relationship between OSA and metabolic and cardiovascular disease complications are required for the prevention and early diagnosis of OSA in Japanese drivers.

Acknowledgments

The authors would like to thank all the subjects who participated in the study and acknowledge the kind support from all co-medical staff in Fukujuji Hospital, Kiyose, Tokyo, Japan.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

References

1) Cui R, Tanigawa T, Sakurai S, Yamagishi K, Iso H. Relationships between sleep-disordered breathing and blood pressure and excessive daytime sleepiness among truck drivers. Hypertens Res. 2006; 29: 605-610
2) Niijima K, Ena K, Hori H, Sashihara S, Mizoue T, Morimoto Y. The usefulness of sleep apnea syndrome screening using a portable pulse oximeter in the workplace. J Occup Health. 2007; 49: 1-8
3) White DP. Sleep-related breathing disorder. Pathophysiology of obstructive sleep apnoea. Thorax.1995; 50: 797-804
4) Bearpark H, Elliott L, Grunstein R, Cullen S, Schneider H, Althaus W, Sullivan C. Snoring and sleep apnea. A population study in Australian men. Am J Respir Crit Care Med. 1995; 151; 1459-1465
5) Kales A, Bixler EO, Cadieux RJ, Schneck DW, Shaw LC. Snoring every night as a risk factor for myocardial infarction: a case-control study. BMJ. 1990; 300: 1557-1558
6) Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342: 1378-1384
7) Spriggs DA, French JM, Murdy JM, James OF, Bates D. Effect of the risk factors for stroke on survival. Neurol Res. 1992; 14: 94-96
8) Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005; 353: 2034-2041
9) D’Alessandro R, Magelli C, Gamberini G, Bacchelli S, Cristina E, Magnani B, Lugaresi E. Snoring every night as a risk factor for myocardial infarction: a case-control study. BMJ. 1990; 300: 1557-1558
10) Franklin KA, Nilsson JB, Sahlin C, Näslund U. Sleep apnoea and nocturnal angina. Lancet. 1995; 345; 1085-1087
11) Kendzerska T, Gershon AS, Hawker G, Tomlinson G, Leung RS. Obstructive sleep apnea and incident diabetes. A historical cohort study. Am J Respir Crit Care Med. 2014; 190: 218-225
12) Elmasry A, Janson C, Lindberg E, Gislason T, Tageldin MA, Boman G. The role of habitual snoring and obesity in the development of diabetes: a 10-year follow-up study in a male population. J Intern Med. 2000; 248: 13-20
13) Lam JC, Mak JC, Ip MS. Obesity, obstructive sleep apnoea and metabolic syndrome. Respirology. 2012; 17: 223-236
14) Coughlin SR, Madowley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J. 2004; 25: 735-741
15) Centers for Disease Control and Prevention. CDC Features- Insufficient sleep is a public health problem. https://www.cdc.gov/features/dssleep/index.html Accessed September 20, 2017
16) US Department of Transportation, National Highway Traffic Safety Administration, National Center on Sleep Disorders Research, National Heart Lung and Blood Institute. Drowsy driving and automobile crashes [National Highway Traffic Safety Administration Web Site]. https://one.nhtsa.gov/people/injury/drowsy_driving1/Drowsy.html#NCSDR/NHTSA Accessed September 20, 2017
17) Ministry of Land, Infrastructure, Transport and Tourism Mar, 2016 Last Accessed September 20, 2017 http://www.mlit.go.jp/common/001149551.pdf in Japanese
18) Takegami M, Suzukato Y, Wakita T, Noguchi H, Chin K, Kadotani H, Inoue Y, Oka Y, Nakamura T, Green J, Johns MW, Fukuhara S. Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. Sleep Med. 2009; 10: 556-565
19) The Report of an American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999; 22: 667-689. Review
20) Erman MK, Stewart D, Einhorn D, Gordon N, Casal E. Validation of the ApneaLink for the screening of sleep apnea: a novel and simple single-channel recording device. J Clin Sleep Med. 2007; 3: 387-392
21) Crowley KE, Rajaratnam SM, Shea SA, Epstein LJ, Czeisler CA, Lockley SW; Harvard Work Hours, Health and Safety Group. Evaluation of a single-channel nasal pressure device to assess obstructive sleep apnea risk in laboratory and home environments. J Clin Sleep Med. 2013; 9: 109-116
22) Ragette R, Wang Y, Weinreich G, Teschler H. Diagnostic performance of single airflow channel recording (ApneaLink) in home diagnosis of sleep apnea. Sleep Breath. 2010; 14: 109-114
23) Nakayama-Ashida Y, Takegami M, Chin K, Sumi K, Nakamura T, Takahashi K, Wakamura T, Horita S, Oka Y, Minami I, Fukuhara S, Kadotani H. Sleep-disordered breathing in the usual lifestyle setting as detected with home monitoring in a population of working men in Japan. Sleep. 2008; 31; 419-425
24) Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S.
The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993; 328: 1230-1235
25) Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013; 177: 1006-1014
26) Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, Malhotra A, Waeb G, Vollenweider P, Tafiti M, Haba-Rubio J. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015; 3: 310-318
27) Tan A, Cheung YY, Yin J, Lim WY, Tan LW, Lee CH. Prevalence of sleep-disordered breathing in a multiethnic Asian population in Singapore: A community-based study. Respir Med. 2016; 21: 943-950
28) Ministry of Health, Labour and Welfare. National health and nutrition survey 2015. http://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukoukoushinka/kekagaiyou.pdf in Japanese. Date last accessed: May 5 2017
29) Kent BD, Grote L, Bonsignore MR, Saarereaanta T, Verbraeck J, Levy P, Sliwinski P, Takaova R, Kvanme JA, Fietze I, Hedner J, McNicholas WT; European Sleep Apnoea Database collaborators. Sleep apnoea severity independently predicts glycemic health in nondiabetic subjects: the ESADA study. Eur Respir J. 2014; 44: 130-139
30) Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med. 2010; 181: 507-513
31) Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T; American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology; American Heart Association Stroke Council; American Heart Association Council on Cardiovascular Nursing; American College of Cardiology Foundation. Sleep apnea and cardiovascular disease: an American Heart Association/american college Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008; 118: 1080-1111
32) Meslier N, Gagnadoux F, Giraud P, Person C, Ouksel H, Urban T, Racineux JL. Impaired glucose-insulin metabolism in males with obstructive sleep apnoea syndrome. Eur Respir J. 2003; 22: 156-160
33) Elmasry A, Lindberg E, Berne C, Janson C, Gislason T, Awad Tageldin M, Boman G. Sleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med. 2001; 249: 153-161
34) West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax. 2006; 61: 945-950
35) American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 34 Suppl 1: S62-S69
36) Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010; 362: 800-811
37) Qaseem A, Dallas P, Owens DK, Starkey M, Holty JE, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014; 161: 210-220
38) Williams JR, Amana A, Tregear SJ. McLean, VA: Manila Consulting Group; 2011. Obstructive sleep apnea and commercial motor vehicle driver safety: updated review. http://ntl.bts.gov/lib/44000/44600/44638/OSA_Update_11302011-p.pdf Date last accessed: April 8 2017
39) U.S. Department of Transportation; Medical examination report for commercial driver fitness determination. U.S. Federal Motor Carrier Safety Administration. http://www.fmcsa.dot.gov/sites/fmcsa.dot.gov/files/docs/Medical_Examination_Report_for_Commercial_Driver_Fitness_Determination_649-F%286045%29.pdf Date last accessed: April 8 2017
40) Jehan S, Masters-Isarilov A, Salifu I, Zizi F, Jean-Louis G, Pandi-Perumal SR, Gupta R, Brzezinski A, McFarlane SI. Sleep disorders in postmenopausal women. J Sleep Disord Ther. 2015; 4
41) Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, Hugert D, Sateia M, Schwab R; Portable Monitoring Task Force of the American Academy of Sleep Medicine. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2007; 3: 737-747